ReviewBiomedical reports2025
VDAC1: The mitochondrial gatekeeper in the battle against hearing loss (Review).
Review in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Autophagy in Sensorineural Hearing Loss: Jekyll or Hyde?International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of hearing loss is strongly associated with mitochondrial damage, particularly downstream of mitochondrial autophagy, which is a process that is coincidentally key for selectively removing damaged mitochondria. Voltage-dependent anion channel 1 (VDAC1) is an important protein in the mitochondrial outer membrane that regulates various essential biological processes, including energy metabolism, calcium ion transport and cell apoptosis. VDAC1 can bidirectionally regulate cell fate, where its oligomerization can exacerbate oxidative stress, leading to cell damage and even death. By contrast, its ubiquitination supports cell survival by regulating mitochondrial autophagy, thereby improving mitochondrial quality control. VDAC1 can significantly contribute to the prevention and management of hearing loss. The present review summarizes how the ubiquitination and oligomerization modifications of VDAC1 can balance cell survival and death, while also exploring current hypotheses on mechanisms associated with hearing loss. These findings emphasize the research prospects of VDAC1 as a novel target for hearing loss treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.